Contraceptive Technology Update – September 1, 2015
September 1, 2015
View Issues
-
Counseling on LARC methods cuts unintended pregnancy rates
Training clinicians to inform women that different birth control methods have very different levels of effectiveness proved key in cutting the number of unintended pregnancies among young women seeking family planning services, data suggests from a new national study from the Bixby Center for Global and Reproductive Health at the University of California, San Francisco.
-
Single-size Caya diaphragm is available by prescription in U.S.
The Caya single-size diaphragm, the first new cervical barrier method to enter the market in more than 10 years, is available by prescription from U.S. healthcare providers.
-
What are the options available for medication prior to IUD placement?
While the American College of Obstetricians and Gynecologists recommends taking over-the-counter pain medication prior to intrauterine device insertion, no specific drug is recommended.
-
Long-acting reversible contraceptives used by few women after delivery
Researchers recently looked at national data to investigate women’s patterns of contraceptive use after delivery and the association between method use and risk of pregnancy within 18 months.
-
Study: Obese teens less likely to use contraception
A study of nearly 1,000 Michigan teens found that sexually active obese adolescents were significantly less likely to use contraception than normal weight peers.
-
Gay, lesbian, and bisexual youth grouped, show increased risk for unintended pregnancy
The United States has seen significant advances in rights for lesbian and gay populations this summer, with the Supreme Court’s decision affirming same-sex marriage nationwide. As we celebrate this victory, however, we remain aware of the many challenges still facing lesbian, gay, and bisexual populations, including health disparities. Many such disparities affect youth, especially in the areas of sexual and reproductive health.
-
Liletta IUD available in the United States
The LILETTA intrauterine device is for sale in the United States. The device was launched through partners Medicines360, a San Francisco-based nonprofit pharmaceutical company, and Actavis, a Dublin, Ireland-based pharmaceutical company.
-
Time to update your clinical practice: 2015 STD Treatment Guidelines available
The Centers for Disease Control and Prevention has released the 2015 STD Treatment Guidelines.
-
Data suggest genital screening misses many STI cases in women
Data from a recent study that looked at more than 10,000 people who attended a Baltimore public health clinic indicate the occurrence of gonorrhea or chlamydia in extragenital areas such as the throat or rectum is significant in women, particularly younger women.
-
Get CDC fact sheet on shigellosis
The Centers for Disease Control and Prevention have a patient information sheet on shigellosis. Shigellosis is a common diarrheal disease caused by a group of bacteria called Shigella.